Principal component directed partial least squares analysis for combining nuclear magnetic resonance and mass spectrometry data in metabolomics: application to the detection of breast cancer.
Nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) are the two most commonly used analytical tools in metabolomics, and their complementary nature makes the combination particularly attractive. A combined analytical approach can improve the potential for providing reliable methods to detect metabolic profile alterations in biofluids or tissues caused by disease, toxicity, etc. In this paper, (1)H NMR spectroscopy and direct analysis in real time (DART)-MS were used for the metabolomics analysis of serum samples from breast cancer patients and healthy controls. Principal component analysis (PCA) of the NMR data showed that the first principal component (PC1) scores could be used to separate cancer from normal samples. However, no such obvious clustering could be observed in the PCA score plot of DART-MS data, even though DART-MS can provide a rich and informative metabolic profile. Using a modified multivariate statistical approach, the DART-MS data were then reevaluated by orthogonal signal correction (OSC) pretreated partial least squares (PLS), in which the Y matrix in the regression was set to the PC1 score values from the NMR data analysis. This approach, and a similar one using the first latent variable from PLS-DA of the NMR data resulted in a significant improvement of the separation between the disease samples and normals, and a metabolic profile related to breast cancer could be extracted from DART-MS. The new approach allows the disease classification to be expressed on a continuum as opposed to a binary scale and thus better represents the disease and healthy classifications. An improved metabolic profile obtained by combining MS and NMR by this approach may be useful to achieve more accurate disease detection and gain more insight regarding disease mechanisms and biology.
Department of Physics, Purdue University, West Lafayette, IN 47907, USA.
Haiwei
H
Gu
Zhengzheng
Z
Pan
Bowei
B
Xi
Vincent
V
Asiago
Brian
B
Musselman
Daniel
D
Raftery
D001943:Breast Neoplasms / Q000097:blood*; D005260:Female; D006801:Humans; D016018:Least-Squares Analysis; D009682:Magnetic Resonance Spectroscopy / Q000379:methods*; D013058:Mass Spectrometry / Q000379:methods*; D055442:Metabolome; D055432:Metabolomics / Q000379:methods*; D025341:Principal Component Analysis
Anal Chem. 2009 Feb 1;81(3):1101-7
19115958
FEBS Lett. 2002 Oct 23;530(1-3):191-6
12387891
Anal Chem. 2006 Jan 15;78(2):363-71
16408915
Expert Rev Mol Diagn. 2008 Sep;8(5):617-33
18785810
Magn Reson Imaging. 2004 Jun;22(5):697-706
15172064
Comput Biol Chem. 2005 Jun;29(3):183-95
15979038
Anal Chem. 2006 Apr 15;78(8):2700-9
16615782
Nat Rev Drug Discov. 2003 Aug;2(8):668-76
12904817
Anal Chem. 2009 Jan 1;81(1):193-202
19117450
J Proteome Res. 2006 Oct;5(10):2642-55
17022635
Anal Chem. 2005 Apr 15;77(8):2297-302
15828760
Mass Spectrom Rev. 2007 May-Jun;26(3):403-31
17405143
Mass Spectrom Rev. 2005 Sep-Oct;24(5):613-46
15389842
Rapid Commun Mass Spectrom. 2006;20(10):1577-84
16628593
J Mass Spectrom. 2007 Sep;42(9):1123-35
17721903
J Proteome Res. 2009 Jan;8(1):352-61
19063642
Nat Rev Drug Discov. 2002 Feb;1(2):153-61
12120097
Anal Chem. 2007 Jan 1;79(1):89-97
17194125
Anal Chem. 2005 Jan 15;77(2):517-26
15649048
Mass Spectrom Rev. 2007 Jan-Feb;26(1):51-78
16921475
Anal Biochem. 2002 Feb 1;301(1):1-7
11811960
Anal Bioanal Chem. 2007 Jan;387(2):539-49
16821030
Anal Bioanal Chem. 2007 Jan;387(2):525-7
16955259
Xenobiotica. 1999 Nov;29(11):1181-9
10598751
Anal Chem. 1995 Mar 1;67(5):793-811
7762816
Chem Commun (Camb). 2007 Feb 28;(8):807-9
17308638
Plant Mol Biol. 2002 Jan;48(1-2):155-71
11860207
J Proteome Res. 2006 Oct;5(10):2780-8
17022649
Science. 2006 Mar 17;311(5767):1566-70
16543450
Expert Rev Mol Diagn. 2006 Sep;6(5):717-31
17009906